Literature DB >> 8984942

Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.

T Stoll1, G Stucki, J Malik, S Pyke, D A Isenberg.   

Abstract

OBJECTIVE: To examine the association among the BILAG disease activity index components and their relations with global assessments, health status, and laboratory tests with regard to the validity of the BILAG index.
METHODS: A cross sectional study of consecutive patients with systemic lupus erythematosus (SLE) attending a specialist lupus outpatient clinic between July 1994 and February 1995. The internal consistency of the British Isles Lupus Assessment Group (BILAG) index-a disease activity assessment system for SLE patients, based on the principle of the physician's intention to treat-was examined using Cronbach's coefficient alpha. The association of the components of the BILAG index with health status as measured with the MOS Short Form 20 (SF-20), with patients' and doctors' global assessments of patient wellbeing and with laboratory tests was analysed with Spearman rank correlations.
RESULTS: 133 female and eight male patients, age 20.1 to 88.7 years (mean 41.1, SD 12.5), were included. With few exceptions, the components of the BILAG index which reflect disease activity in different organ systems were not associated with each other. With the exception of the mucocutaneous component, we found a significant relation between all components of BILAG and global assessment of patient wellbeing, health status, erythrocyte sedimentation rate, or serum C3 level.
CONCLUSIONS: The study confirms the validity of all but the mucocutaneous component of the BILAG index. However, disease activity in different organ systems in SLE does not follow a common pattern. Thus the individual BILAG components should be used rather than the total BILAG score as a primary endpoint in clinical and epidemiological studies. To capture the total effect of SLE on an individual measures of disease activity, damage, and health status are all needed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984942      PMCID: PMC1010295          DOI: 10.1136/ard.55.10.756

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument.

Authors:  T Wachtel; J Piette; V Mor; M Stein; J Fleishman; C Carpenter
Journal:  Ann Intern Med       Date:  1992-01-15       Impact factor: 25.391

2.  Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG).

Authors:  D P Symmons; J S Coppock; P A Bacon; B Bresnihan; D A Isenberg; P Maddison; N McHugh; M L Snaith; A S Zoma
Journal:  Q J Med       Date:  1988-11

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

5.  Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype.

Authors:  M R Ehrenstein; C M Longhurst; D S Latchman; D A Isenberg
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

Authors:  E M Hay; P A Bacon; C Gordon; D A Isenberg; P Maddison; M L Snaith; D P Symmons; N Viner; A Zoma
Journal:  Q J Med       Date:  1993-07

7.  Useful laboratory measurements in the management of systemic lupus erythematosus.

Authors:  W J Morrow; D A Isenberg; A Todd-Pokropek; H F Parry; M L Snaith
Journal:  Q J Med       Date:  1982

8.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

Authors:  M H Liang; S A Socher; M G Larson; P H Schur
Journal:  Arthritis Rheum       Date:  1989-09

9.  The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus.

Authors:  E W Karlson; L H Daltroy; R A Lew; E A Wright; A J Partridge; W N Roberts; S H Stern; K V Straaton; M C Wacholtz; J M Grosflam
Journal:  Arthritis Rheum       Date:  1995-02

10.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

  10 in total
  13 in total

1.  Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Marisa S Klein-Gitelman; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

Review 3.  Top 10 things to know about lupus activity measures.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

4.  Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Kristina Wiers; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Marisa S Klein-Gitelman; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

5.  Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.

Authors:  Tamar Rubinstein; Milena Pitashny; Benjamin Levine; Noa Schwartz; Julie Schwartzman; Elena Weinstein; Jose M Pego-Reigosa; Tim Y-T Lu; David Isenberg; Anisur Rahman; Chaim Putterman
Journal:  Rheumatology (Oxford)       Date:  2010-02-09       Impact factor: 7.580

6.  Belimumab in systemic lupus erythematosus: an update for clinicians.

Authors:  Susan S Kim; Kyriakos A Kirou; Doruk Erkan
Journal:  Ther Adv Chronic Dis       Date:  2012-01       Impact factor: 5.091

7.  Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity.

Authors:  Claas H Hinze; Michiko Suzuki; Marisa Klein-Gitelman; Murray H Passo; Judyann Olson; Nora G Singer; Kathleen A Haines; Karen Onel; Kathleen O'Neil; Earl D Silverman; Lori Tucker; Jun Ying; Prasad Devarajan; Hermine I Brunner
Journal:  Arthritis Rheum       Date:  2009-09

8.  Novel evidence-based systemic lupus erythematosus responder index.

Authors:  Richard A Furie; Michelle A Petri; Daniel J Wallace; Ellen M Ginzler; Joan T Merrill; William Stohl; W Winn Chatham; Vibeke Strand; Arthur Weinstein; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

Review 9.  Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).

Authors:  Juanita Romero-Diaz; David Isenberg; Rosalind Ramsey-Goldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

Review 10.  Disease activity assessment in SLE: do we have the right instruments?

Authors:  Michelle Petri
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.